As of Feb 21, 2025, the CRL stock has a PE ratio of 815.1. The calculation is based on the latest EPS of $0.2 and the stock price of $163.02 per share. The PE ratio currently is comparable to its last four-quarter average.
The mean historical PE ratio of Charles River Laboratories International over the last ten years is 52.73. The current 815.1 P/E ratio is similar to the historical average. Looking back at the last ten years, CRL's PE ratio peaked in the Dec 2024 quarter at 930.8, with a price of $186.16 and an EPS of $0.2. The Apr 2023 quarter marked the lowest point at 20.68, with a price of $201.82 and an EPS of $9.76.
Maximum annual increase: 3,550.2% in 2024
Maximum annual decrease: -52.08% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 930.8 | 3,550.2% | $186.16 | $0.2 |
2023 | 25.5 | 11.99% | $236.4 | $9.27 |
2022 | 22.77 | -52.08% | $217.9 | $9.57 |
2021 | 47.52 | 38.74% | $369.2 | $7.77 |
2020 | 34.25 | 16.54% | $251.71 | $7.35 |
2019 | 29.39 | 24.17% | $151.93 | $5.17 |
2018 | 23.67 | -43.78% | $111.72 | $4.72 |
2017 | 42.1 | 81.78% | $109.45 | $2.6 |
2016 | 23.16 | -7.17% | $76.19 | $3.29 |
2015 | 24.95 | 5.54% | $80.08 | $3.21 |
2014 | 23.64 | -4.68% | $64.29 | $2.72 |
2013 | 24.8 | 36.49% | $53.33 | $2.15 |
2012 | 18.17 | 43.64% | $36.88 | $2.03 |
2011 | 12.65 | N/A | $27.33 | $2.16 |
2010 | N/A | N/A | $35.7 | -$5.38 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 930.8 | 3,679.13% | $186.16 | $0.2 |
Sep 2024 | 24.63 | 0.29% | $198.31 | $8.05 |
Jun 2024 | 24.56 | -22.5% | $206.58 | $8.41 |
Mar 2024 | 31.69 | 24.27% | $270.95 | $8.55 |
Dec 2023 | 25.5 | 21.03% | $236.4 | $9.27 |
Sep 2023 | 21.07 | -4.79% | $195.98 | $9.3 |
Jul 2023 | 22.13 | 7.01% | $210.25 | $9.5 |
Apr 2023 | 20.68 | -9.18% | $201.82 | $9.76 |
Dec 2022 | 22.77 | 4.69% | $217.9 | $9.57 |
Sep 2022 | 21.75 | -15.73% | $187.51 | $8.62 |
Jun 2022 | 25.81 | -22.52% | $226.32 | $8.77 |
Mar 2022 | 33.31 | -29.9% | $279.1 | $8.38 |
Dec 2021 | 47.52 | -17.88% | $369.2 | $7.77 |
Sep 2021 | 57.87 | 24.88% | $458.3 | $7.92 |
Jun 2021 | 46.34 | 21.31% | $367.9 | $7.94 |
CRL's current PE ratio is higher than the 3, 5 and 10-year averages.
In comparison to its peer stock TMO, CRL's PE ratio is higher.
Stock name | PE ratio | Market cap |
---|---|---|
TMO Thermo Fisher Scientific Inc | 32.12 | $200.91B |
CRL Charles River Laboratories International Inc | 815.1 | $8.34B |
RGEN Repligen Corp | N/A | $8.91B |
SCYX Scynexis Inc | N/A | $40.61M |
CRL stock has a price to earnings ratio of 815.1 as of Feb 21, 2025.
As an average over the last 3 years, CRL stock has a PE ratio of 100.39.
As an average over the last 5 years, CRL stock has a PE ratio of 76.01.
Over the last ten years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 930.8.
CRL's current price to earnings ratio is 1,446% above its 10-year historical average.
CRL's PE ratio is high because its earnings per share (EPS) is low relative to its stock price.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Feb 21, 2025), Charles River Laboratories International's share price is $163.02. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.2. Therefore, Charles River Laboratories International's PE ratio for today is 815.1. PE RATIO(815.1) = STOCK PRICE($163.02) / TTM EPS($0.2)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.